When was Achieve Life Sciences founded?

Achieve Life Sciences was founded in 1991 and raised its 1st funding round 29 years after it was founded.

Where is Achieve Life Sciences located?

Achieve Life Sciences is headquartered in Seattle, United States.

Who is the current CEO of Achieve Life Sciences?

John Bencich of Achieve Life Sciences.

How many employees does Achieve Life Sciences have?

As of Sep 30, 2026, the latest employee count at Achieve Life Sciences is 45.

Is Achieve Life Sciences a funded company?

Achieve Life Sciences is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Apr 30, 2020.

When was the latest funding round of Achieve Life Sciences?

Achieve Life Sciences' latest funding was a $***** Post IPO round on Apr 21, 2026, with participation from 5 investors.

Where does Achieve Life Sciences rank among its competitors?

Achieve Life Sciences ranks 6th amongst 56 active competitors, of which 15 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Adial Pharmaceuticals, which secured $64M in Jun, 2026.

Who are the top competitors of Achieve Life Sciences?

Achieve Life Sciences' top competitors include Indivior, Adial Pharmaceuticals and Aelis Farma. Among them, Adial Pharmaceuticals secured the most recent funding round in June, 2026.

Achieve Life Sciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Achieve Life Sciences is a public company based in Seattle (United States), founded in 1991. It operates as a Developer of plant-based alkaloid for treating smoking cessation. Achieve Life Sciences has raised an undisclosed amount in funding from investors like TPG, VenBio and Marshall Wace. The company has 56 active competitors, including 15 funded and 14 that have exited. Its top competitors include companies like Indivior, Adial Pharmaceuticals and Aelis Farma.

Company Details

Developer of plant-based alkaloid for treating smoking cessation. The company is developing Cytisinicline, which is a plant-based alkaloid with a binding affinity to the α4β2 nicotine receptor. The candidate is expected to block nicotine cravings and reduce the severity of nicotine withdrawal symptoms.

Website: achievelifesciences.com
Email ID: *****@achievelifesciences.com
Phone Number: +1 **********

Key Metrics

Founded Year

1991

Location

Seattle, United States

Stage

Public

Latest Funding Round

Post IPO, Apr 21, 2026, $*****

Investors

TPG & 8 more

Ranked

6^th among 56 active competitors

Employee Count

45 as on Sep 30, 2026

Investment & Acquisitions

OncoGenex & 1 more

Similar Companies

Indivior & 61 more

Exit Details

Public

View Achieve Life Sciences' full profile

Achieve Life Sciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Achieve Life Sciences, Inc. CIN: 949858 , United States, Active	May 23, 1996	-	-	-
ACHIEVE LIFE SCIENCES INC. CIN: 954343413 , United States, Active	Dec 31, 1999	-	15 (As on Dec 31, 2024)	-

Achieve Life Sciences got listed on Oct 30, 1995.

Click here to take a look at Achieve Life Sciences's IPO in detail

Achieve Life Sciences has raised funding over 5 rounds. Its first funding round was on Apr 30, 2020. Its latest funding round was a Post IPO round on Apr 21, 2026 for $*****. 5 investors participated in its latest round. Achieve Life Sciences has 9 institutional investors.

Here is the list of recent funding rounds of Achieve Life Sciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 21, 2026	8814860	Post IPO	6243759	4026710	4447262	2730552
Feb 29, 2024	4774422	Post IPO	4731649	6130610	4700505	Propel Bio Partners & 2 more
Nov 15, 2022	9093781	Post IPO	7121964	7042965	5397866	8656778

Access funding benchmarks and valuations. Sign up today!

View details of Achieve Life Sciences's funding rounds and investors

Achieve Life Sciences' employee count trend

Achieve Life Sciences has 45 employees as of Sep 26. Here is Achieve Life Sciences's employee count trend over the years:

Employee count trend for Achieve Life Sciences

Uncover Achieve Life Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Achieve Life Sciences include Indivior, Adial Pharmaceuticals and Aelis Farma. Here is the list of Top 10 competitors of Achieve Life Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Indivior 2014, Richmond Hill (United States), Public	Therapeutics for addiction treatment	-	Digital Pharma Lab, Athyrium Capital Management ... & 1 others	65/100
2nd	Adial Pharmaceuticals 2010, Charlottesville (United States), Public	Developer of therapeutics for the treatment of addictions	$7.7M	Coastlands Capital, Boxer Capital & 3 others	57/100
3rd	Aelis Farma 2013, Bordeaux (France), Public	Developer of small molecule drugs targeting CB1 receptor for CNS diseases	$14M	Bpifrance, Inserm Transfert & 10 others	56/100
4th	Braeburn 2012, Philadelphia (United States), Series D	Developing long acting formulation for opioid addiction	$110M	RA Capital Management, New Leaf Venture Partners ... & 5 others	56/100
5th	Ethypharm 1977, Saint Cloud (France), Acquired	Developer of therapies for the treatment of pain and addiction	$248M	Astorg Partners, Biovail & 7 others	55/100
6th	Achieve Life Sciences 1991, Seattle (United States), Public	Developer of plant-based alkaloid for treating smoking cessation	-	Marshall Wace, Frazier Life Sciences & 7 others	56/100
7th	Myosin Therapeutics 2020, Jupiter (United States), Seed	Developer of therapeutics for CNS-based disorders	$6M	Florida Opportunity Fund, DeepWork Capital ... & 7 others	53/100
8th	Biotie 1998, Turku (Finland), Acquired	Commercial Stage biotech company developing drugs against CNS disease.	$150M	Foresite Capital, Versant Ventures & 10 others	50/100
9th	Titan Pharma 1992, San Francisco (United States), Public	A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases	-	Blue Harbour Asset Management, Gates & 5 others	50/100
10th	DemeRx 2010, Miami (United States), Series A	Developer of non-addicting alternatives for opioid de-addiction	$5.43M	-	49/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Achieve Life Sciences's competitors? Click here to see the top ones

Achieve Life Sciences has acquired 2 companies including OncoGenex and OncoGenex. Achieve Life Sciences has not made any investments as of now.

Here is the latest report on Achieve Life Sciences's sector:

Free

Neurology - Sector Report

Edition: August, 2026 (73 Pages)

View all reports related to Achieve Life Sciences

Media has covered Achieve Life Sciences for a total of 22 events in the last 1 year, 12 of them have been about company updates and 4 about people movement.